Life sciences companies need to take further steps to protect themselves against the growing problem of counterfeit drugs
When talking about counterfeiting, most of us think about major consumer brands but, unfortunately, counterfeiting is also a major and growing problem within the life sciences industry – and to make matters worse, nobody knows exactly how big the problem is.
Financial results for Q2 2021 just released: Group revenue up 1.3%
In Q2, we saw continued strong growth within the Life Sciences International business, and we strengthened this business further with the addition of SL Controls. Once again, our Winning Solutions strategy gained traction, as it now constitutes 52% of NNIT’s revenue compared to 44% in the same period last year.
Helping veterans kick off a civilian career
As part of our corporate responsibility work, we support the initiative Velkommen Hjem (welcome home), a Danish organization working to ease the transition to a civilian career for military veterans. Members of NNIT’s management have volunteered to act as mentors, helping to prepare veterans for a new start.
NNIT executive selected for PharmaVOICE 100
Brooke Casselberry recognized as one of industry’s most inspiring
NNIT further strengthens its Production IT solutions with the acquisition of Irish-based SL Controls
NNIT and SL Controls have agreed to join forces. SL Controls will further strengthen NNIT’s solutions within Production IT and is yet another step towards consolidating the NNIT Group as one of the foremost suppliers of IT services to the global life sciences industry.
NNIT’s new CEO is all in
Pär Fors was on sabbatical, contemplating his next executive challenge when he was approached by NNIT’s Board of Directors. As talks progressed, it became clear that NNIT fit the bill: a CEO role within the tech industry, in a company with a clear and ambitious strategy for international expansion, but slightly different to other players due to its focus on life science.
Financial results for Q1 2021 just released: Group revenue up 1.2%
In Q1, we experienced continued strong growth within the International Life Sciences business, with Excellis performing to plan. Our Private & Public business started to see positive momentum in relation to the Winning Solutions strategy, which now constitutes 49% of NNIT’s revenue.
Lonza and NNIT partner to speed up MES projects
Across the life sciences industry, pharma companies are seeking new ways to respond to the high agility required to produce complex products like personalized cancer treatment, cell and gene therapy and Covid-19 vaccines. Central to these efforts is the manufacturing execution system (MES), which allows pharma companies to adopt pharma 4.0 production and manage their data flows to expedite product
NNIT to support COVID-19 vaccine safety data capture
NNIT, a trusted partner of AstraZeneca’s since 2014, will be implementing the critical COVID-19 vaccine post-marketing safety data system.
Acquisition-boosted Orifarm selects NNIT as new strategic IT partner
Orifarm and NNIT have signed a contract for the delivery of end-to-end IT services in connection with Orifarm’s acquisition of a significant portfolio of select over-the-counter (OTC) and prescription pharmaceutical products from Japanese pharmaceutical giant Takeda.
NNIT signs largest Veeva deal to date
NNIT recently signed its largest Veeva deal to date with a global top-10 life sciences company.
An expert in transition and transformation
NNIT’s new CFO, Pernille Fabricius, is a change management enthusiast: “I welcome and embrace change, and I enjoy leading an organization through a transformation process to stimulate growth and lasting value across the board. That’s what I’ve been doing throughout my career, and it’s what motivates me”.